Peri-Procedural Myocardial Infarction, Platelet Reactivity, Thrombin Generation, and Clot Strength: Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin
Coronary Artery Disease
About this trial
This is an interventional treatment trial for Coronary Artery Disease
Eligibility Criteria
Inclusion Criteria: Subjects (men or women) aged ³ 18 Patients undergoing elective coronary stenting (200 patients) Exclusion Criteria: ST-segment elevation myocardial infarction within 48 hours prior to randomization Prior PCI within previous 4 weeks of randomization or planned staged PCI within the subsequent month. Cardiogenic shock > 50% unprotected left main stenosis Any low molecular weight heparin within the prior 12 hours Treatment with any P2Y12 blocker (Plavix or Ticlid) within the previous 14 days before randomization Treatment with any platelet GPIIb/IIIa inhibitor within the previous 30 days before randomization Concurrent treatment with warfarin History of bleeding diathesis, or evidence of active abnormal bleeding within 30 days of randomization. History of hemorrhagic stroke at any time, or stroke or TIA of any etiology within 30 days of randomization. Major surgery within 6 weeks prior to randomization. Known platelet count of <100,000/mm3. PT > 1.5 X control HCT < 25% Known allergy or contraindication to eptifibatide, heparin, aspirin or plavix. Participation in a study of experimental therapy or device 30 days prior to randomization. Creatinine level of greater than 2.0 mg/dl or a creatinine clearance <30mL Known history of alcohol or drug abuse Pregnant women or women of child bearing potential not using an acceptable method of contraception.
Sites / Locations
- Sinai HospitalRecruiting